Association of Clinical Events With Everolimus Exposure in Kidney Transplant Patients Receiving Low Doses of Tacrolimus

A key objective in the use of immunosuppression after kidney transplantation is to attain the optimal balance between efficacy and safety. In a phase 3b, multicenter, randomized, open‐label, noninferiority study, the incidences of clinical events, renal dysfunction, and adverse events (AEs) were ana...

Descripción completa

Detalles Bibliográficos
Autores principales: Shihab, F., Qazi, Y., Mulgaonkar, S., McCague, K., Patel, D., Peddi, V. R., Shaffer, D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5600116/
https://www.ncbi.nlm.nih.gov/pubmed/28141897
http://dx.doi.org/10.1111/ajt.14215

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5600116/
https://www.ncbi.nlm.nih.gov/pubmed/28141897
http://dx.doi.org/10.1111/ajt.14215

Ejemplares similares